[Effect of solcoseryl and combined therapy of solcoseryl and FT-207 for mice bearing meth-A tumor].
The effects of a combined chemotherapy of solcoseryl and FT-207 on tumor growth, delayed hypersensitivity and cell population of the spleen were studied using inbred BALB/c mice. Meth-A tumor cells (2 X 10(6] were inoculated into the back of 5 to 6 week old BALB/c male mouse. Animals were divided into three groups: Solcoseryl group, in which 0.04 mg of solcoseryl was injected intravenously three times before inoculation and four times after inoculation; Combined group, in which 1.2 mg of FT-207 and 0.04 mg of solcoseryl were injected intravenously four times after inoculation; FT-207 group, in which 1.2 mg of FT-207 was injected four times after inoculation, with out solcoseryl administration. Following results were obtained: Solcoseryl group showed enhanced immunity and tumor suppression; Decreased immunity due to FT-207 was recovered by administration of solcoseryl but no tumor suppression was observed and, Decreased T-cell population of spleen due to FT-207 was recovered by administration of solcoseryl. These facts suggested that solcoseryl was useful because of making recovery possible from decreased immunity due to chemotherapy.
D000183:Actihaemyl / Q000008:administration & dosage*; D000818:Animals; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives*; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology; D005641:Tegafur / Q000008:administration & dosage*; D014020:Tissue Extracts / Q000008:administration & dosage*
D014020:Tissue Extracts; D005641:Tegafur; D000183:Actihaemyl; D008748:Methylcholanthrene; D005472:Fluorouracil